Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genolimzumab (GB226) Phase I Safety and PK Study
NCT03374007Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Oct 2017
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of geptanolimab in solid tumor (advanced stage) and lymphoma, sponsored by Genor Biopharma. Primary endpoints: Adverse Event, Serious Adverse Event and 2 more. Status: unknown.
02
Drugs
geptanolimab
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03374007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374007.